PartnershipApr 13, 2026, 06:31 AM
Telix & Regeneron Partner for Radiopharmaceuticals; Telix Gets $40M Upfront
AI Summary
Telix Pharmaceuticals and Regeneron Pharmaceuticals announced a collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies. The partnership leverages Telix's radiopharmaceutical platform and Regeneron's antibody expertise, focusing on solid tumor targets and radio-diagnostics. Telix will receive an upfront payment of US$40 million for four initial programs and has the option to either co-fund and profit-share or earn up to US$2.1 billion in milestones plus royalties for individual programs.
Key Highlights
- Telix receives US$40 million upfront payment from Regeneron.
- Potential for up to US$2.1 billion in development and commercial milestones.
- Low double-digit royalties on future net sales for opted-out programs.
- Collaboration includes 50/50 cost and profit-sharing for co-commercialization.
- Partnership covers four initial therapeutic programs, with option for four more.